Case Report Open Access
Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jun 16, 2022; 10(17): 5825-5832
Published online Jun 16, 2022. doi: 10.12998/wjcc.v10.i17.5825
Ultrasound-guided microwave ablation as a palliative treatment for mycosis fungoides eyelid involvement: A case report
Yan-Wei Chen, Hai-Zhen Yang, Shuang-Shuang Zhao, Zheng Zhang, Zhe-Ming Chen, Hua-Hui Feng, Mao-Hui An, Ke-Ke Wang, Ran Duan, Bao-Ding Chen
Yan-Wei Chen, Hai-Zhen Yang, Shuang-Shuang Zhao, Zheng Zhang, Zhe-Ming Chen, Hua-Hui Feng, Mao-Hui An, Ke-Ke Wang, Ran Duan, Bao-Ding Chen, Department of Medical Ultrasound, The Affiliated Hospital of Jiangsu University, Zhenjiang 212000, Jiangsu Province, China
ORCID number: Yan-Wei Chen (0000-0002-1486-1755); Hai-Zhen Yang (0000-0002-5500-2922); Shuang-Shuang Zhao (0000-0001-7269-5479); Zheng Zhang (0000-0003-1702-0553); Zhe-Ming Chen (0000-0002-4245-4794); Hua-Hui Feng (0000-0003-3575-5019); Mao-Hui An (0000-0002-5282-8761); Ke-Ke Wang (0000-0003-0587-7090); Ran Duan (0000-0002-3469-2928); Bao-Ding Chen (0000-0001-9559-9199).
Author contributions: Chen YW, Wang KK and An MH contributed to collecting the data; Chen YW and Yang HZ were responsible for writing and editing the manuscript; Chen BD and Duan R performed the operation; Zhao SS, Zhang Z, Chen ZM and Feng HH reviewed the manuscript; all authors read and approved the final manuscript.
Supported by Zhenjiang Social Development Fund, No. SH2021028; Zhenjiang Social Development Fund, No. SH2018035; and the “169” Project of Zhenjiang City, No. YLJ201931.
Informed consent statement: Written informed consent was obtained from the patient for publication of this case report and accompanying images before the microwave ablation.
Conflict-of-interest statement: The authors report no conflicts of interest in this work.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016) and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Bao-Ding Chen, MD, Doctor, Professor, Department of Medical Ultrasound, The Affiliated Hospital of Jiangsu University, No. 438 Jiefang Road, Zhenjiang 212000, Jiangsu Province, China. alphalife@163.com
Received: December 6, 2021
Peer-review started: December 6, 2021
First decision: March 7, 2022
Revised: March 11, 2022
Accepted: April 3, 2022
Article in press: April 3, 2022
Published online: June 16, 2022

Abstract
BACKGROUND

Mycosis fungoides (MF) is a form of lymphoma derived from heterogeneous T cells, and eyelid involvement is extremely rare. The common methods to treat eyelid involvement are radiotherapy and chemotherapy, but their efficacies are limited. Herein, we report a case of advanced-stage MF eyelid involvement, propose ultrasound (US)-guided microwave ablation (MWA) therapy and present a literature review.

CASE SUMMARY

A male patient was admitted to our hospital in June 2018 and diagnosed with MF via radiological and histopathological examinations. The patient’s condition was not well controlled by various conventional chemotherapies. US-guided MWA was performed to relieve the patient’s symptoms and improve his quality of life, showing satisfactory efficacy.

CONCLUSION

Eyelid involvement is one of the most troublesome clinical problems for advanced-stage MF patients. This is the first report on the use of US-guided MWA as a palliative therapy for MF eyelid involvement; the treatment successfully relieved the patient’s clinical symptoms and reduced his anxiety behaviours. Our study sheds new light on methods for improving the clinical management of eyelid involvement in MF.

Key Words: Mycosis fungoides, Cutaneous lymphomas, Eyelid involvement, Microwave ablation, Palliative care, Case report

Core Tip: In this case report, we propose the use of ultrasound-guided percutaneous microwave ablation for the treatment of advanced mycosis fungoides eyelid involvement. Compared with traditional surgical methods, it has less trauma, faster recovery and fewer side effects. As a palliative treatment method, it can greatly alleviate the patient's clinical symptoms and improve the quality of life.



INTRODUCTION

Mycosis fungoides (MF) is the most common form of cutaneous T-cell lymphoma (CTCL), accounting for approximately 50% of all cutaneous primary lymphomas[1]. Most MF patients show a chronic course with slow progression; however, nonspecific features such as skin patches and plaques can result in misdiagnoses and rapidly progressing disease[2]. Advanced-stage MF has a worse prognosis, and only a few patients achieve long-term survival with allogeneic stem cell transplantation[3]. Ultrasound (US)-guided microwave ablation (MWA) is a novel method for inoperable tumours and has been proven to be effective for various tumours, namely, lung, prostate, breast, colon, rectum, lung and cervix cancers[4]. The main purpose of palliative MWA for malignancies is to reduce tumour burden, control tumour progression and achieve symptom relief[5]. Here, we described the case of a male patient treated with US-guided MWA for MF eyelid involvement.

CASE PRESENTATION
Chief complaints

A 52-year-old man was admitted to our hospital in March 2020 because of continuous enlargement of the left eyelid mass with swelling and pain.

History of present illness

The patient initially presented to our hospital with small hard bulges that emerged from both facial aspects after a frontofacial crash in June 2018. The rash tissue on the right side of the patient’s face was biopsied and confirmed to be MF by histopathology. The patient subsequently received twelve courses of COP (cyclophosphamide 400 mg day 1-5; prednisone 100 mg day 1-5; vincristine 2 mg day 1). Chidamide was suggested after rapid disease progression, but the patient refused it initially for economic reasons. In August 2019, the patient presented with swelling of the left orbital tissue and severe skin rashes on the forehead and cheeks. CVP (cyclophosphamide 1200 mg day 1; vincristine 2 mg day 1; prednisone 100 mg day 1-5), DHAX (oxaliplatin 250 mg day 1; cytarabine 3300 mg day 2; dexamethasone 40 mg day 1-4) and CHOPE (doxorubicin 80 mg day 1; vincristine 2 mg day 1; cyclophosphamide 1200 mg day 1; prednisone 100 mg day 1-5; etoposide 100 mg day 1-3) regimens were attempted continuously, but the eyelid mass and rashes were not significantly improved.

History of past illness

The patient was diagnosed with syphilis two years prior and received treatment.

Personal and family history

There was no relevant personal or family history.

Physical examination

Physical examination revealed that the skin was scattered with rashes, and a palpable mass approximately 2 cm × 2 cm in size with tenderness was detected in the right groin. There were multiple skin masses and plaque-like rashes on the frontal face; the largest was an approximately 3 cm × 4 cm mass on the left eyelid.

Laboratory examinations

During hospitalization, the patient’s leukocyte count was 13.5 × 109/L (reference range: 3.5-9.5 × 109/L), his lymphocyte ratio was 14.7% (reference range: 20%-50%), the monocyte ratio was 13.3% (reference range: 3%-10%), his red blood count was 3.18 × 1012/L (reference range: 4.3-5.8 × 1012/L), and high-the sensitivity C-reactive protein (hsCRP) level was 24.2 mg/L (reference range: 0-10 mg/L). Blood smear examination showed that the mature lymphocyte ratio was 15.0% (reference range: 20%-50%). The increased white blood cell count and hsCRP level were considered complications of infection caused by bone marrow suppression after chemotherapy.

Imaging examinations

Abnormal fluorodeoxyglucose (FDG) uptake in multiple organs and lymph nodes throughout the body was identified with 18F-FDG positron-emission tomography (PET)-computed tomography (CT) (Figure 1).

Figure 1
Figure 1 Positron emission tomography-computed tomography examination. A: Computed tomography (CT) examination detected enlarged lymph node in the right inguinal region; B: Positron emission tomography (PET) images showed that metabolism was obviously increased in the enlarged lymph node; C: PET-CT fusion image; D: The image of PET in the coronal plane indicated abnormal fluorodeoxyglucose accumulation in the whole body.

Orbital CT showed swelling of the facial, periorbital and intraorbital soft tissues on the left side with mass shadows and compression of the left eyeball and extraocular muscle (Figure 2).

Figure 2
Figure 2 Orbital computed tomography. A: The orbital computed tomography (CT) image in June 2019 showed slightly swelling surrounded the eyes; B: Preoperative orbital CT in April 2020 indicated that left eyeball and extra-ocular muscle were compressed; C: Postoperative orbital CT 3 mo after microwave ablation.

US images showed a mass 24.8 mm × 45.5 mm in size in the left upper eyelid. Colour Doppler flow imaging (CDFI) and contrast-enhanced ultrasound (CEUS) showed abundant blood flow signals in the mass (Figure 3).

Figure 3
Figure 3 Preoperative sonography of the eyelid mass. A: Preoperative ultrasonography of the eyelid mass; B: Colour Doppler flow imaging showed the mass was rich in blood flow signals; C: Marked contrast enhancement of the mass was observed via contrast-enhanced ultrasound.

Pathological examination of the facial skin revealed a T cell proliferative disease. Immunohistochemical staining revealed that the tumour was positive for CD3, CD4, CD5, CD8, CD45RO, CD20, CD79a, Ki67 (+ = 40%) and EMA, but negative for CD56, CD30, GR-B, and EBEV (Figure 4).

Figure 4
Figure 4 Pathological examination of the facial skin. A: Magnification: 200 ×; B: Magnification: 400 ×.
FINAL DIAGNOSIS

The patient was diagnosed with MF involving the left eyelid.

TREATMENT

The doctors ruled out radical resection due to the patient’s condition. Given the unsatisfactory effect of chemotherapy, US-guided MWA was recommended in May 2020 as a palliative treatment to alleviate the symptoms of ocular compression and pain. An ECO-100A1 microwave therapeutic system (Nanjing ECO Microwave System Co., Ltd., Nanjing, China) consisting of a microwave generator, a hollow water-cooled shaft antenna (16 Guage) and a flexible coaxial cable (Figure 5A and B) was employed, and the whole ablation process was monitored by US in real-time. The optimal puncture paths were determined with the guidance of ultrasonography. Lidocaine (2%, 10 mL) was injected for topical anaesthesia, while saline (20 mL) was used to protect the surrounding tissues. The needle pin was accurately inserted into the eyelid mass under ultrasonic dynamic monitoring to initiate MWA treatment with a microwave instrument with a power output of 35 W. The echogenicity of the microwave needle was continuously enhanced with the release of microwave energy (Figure 5C), while moving-spot technology was used to ensure complete ablation. Ablation was accomplished when CDFI revealed no blood flow signal and when no distinct enhancement was detected in the mass by CEUS. The ablation procedure took 6 minutes and 10 s in total, and the patient recovered well postoperatively. The patient received 4 courses of the CVP (cyclophosphamide 300 mg day 1-5; vincristine 2 mg day 1; dexamethasone 10 mg day 1-5) chemotherapy regimen after MWA.

Figure 5
Figure 5 Procedure and follow-up of microwave ablation. A: The disposable microwave therapeutic antenna; B: The microwave ablation was performed under ultrasound guidance; C: Ultrasound image showed microwave energy was being released; D: One day before microwave ablation; E: One week after microwave ablation; F: Two weeks after microwave ablation.
OUTCOME AND FOLLOW-UP

Macroscopic examination showed that the eyelid mass had decreased in size, and the patient reported significant alleviation of the compression-related symptoms after MWA (Figure 5D-F). Three months later, re-examination via orbital CT indicated that eyeball compression and deformation were significantly improved. Anti-PD1 monoclonal antibody or anti-CD30 monoclonal antibody therapy was recommended to prevent disease progression, but the patient refused further treatment and died in January 2021.

DISCUSSION

MF is the most frequent subtype of CTCL and belongs to a group of heterogeneous T cell-derived extranodal non-Hodgkin lymphomas[6]. Diagnosis of MF in the early stages is challenging and requires a combination of clinical, pathological and immunohistochemical analyses[7]. Although the survival time of early-stage MF patients is similar to that of the general population, those with advanced-stage MF have poor prognoses and a median survival time under five years[8]. Regrettably, many patients miss optimal opportunities for treatment due to misdiagnosis. Systemic treatments (biological and targeted therapies) alone or combined with skin-directed therapies and chemotherapies are the most common interventions for advanced-stage MF. Although many patients initially respond well to treatment, the duration of this response is limited[9]. The aim of the aforementioned treatments for patients with advanced MF is to alleviate symptoms and improve quality of life; stem cell transplantation is currently the only method that provides an opportunity to achieve radical cure[10,11]. Many patients cannot easily access systemic and standard treatments for various reasons, such as poor economic status and limited access to medical care.

In this case, concurrent involvement of the left upper eyelid was observed in a patient with advanced-stage MF. He experienced persistent mechanical ocular compression and pus discharge from the large mass. Although chemotherapy provided some relief, the mass rapidly increased after chemotherapy ended, causing the patient substantial physical and psychological stress. Surgical excision was considered risky and likely to lead to infection due to the patient’s poor general condition. Percutaneous thermal ablation is a minimally invasive approach that creates a smaller wound than surgery and is easier to heal from. Percutaneous thermal or energy-based ablation for various tumours under real-time imaging guidance has been widely applied since the 1990s[12]. The most frequently used high temperature-based techniques in recent years are MWA and radiofrequency ablation. Hyperthermic injury caused by thermal ablation damages the cell membrane via direct or indirect mechanisms, inducing cell death and tumour destruction[13]. Compared to radiofrequency, microwave energy produces greater temperatures and covers larger areas; thus, MWA is superior for treating large tumours[14]. Furthermore, areas treated with MWA generally show clearer boundaries than those treated with other thermal therapies[15]. Consistent with our expectations, the mass rapidly reduced in size when chemotherapy was combined with MWA. Moreover, the patient’s ocular compression and pus discharge symptoms markedly improved, and he regained some perception of light. While the mass increased in size again two months later, the patient reported obvious attenuation of ocular compression, which was also evidenced by a CT scan in August 2020. We considered that even though MWA failed to completely eradicate the mass, coagulation necrosis of the tissue caused by the high temperature may have prevented further intraorbital infiltration to some extent[16].

Eyelid involvement in MF is not frequently reported, and local percutaneous thermal ablation for this neoplasia has not been previously attempted. We reviewed the literature published over the past two decades (from 2000 to 2021) in PubMed (https://pubmed.ncbi.nlm.nih.gov/) and seven cases of MF eyelid involvement were retrieved (Table 1)[17-22]. Almost all the patients were male except one 33-year-old female, and the average age was 59 years. In five cases with inconsistent outcomes, overall survival times were not significantly affected by local radiotherapy, psoralen ultraviolet A therapy or non-local treatment. These findings are likely ascribable to the advanced stage of the disease and the poor overall condition of the patients; thus, the patients only survived for a number of months after diagnosis. Only one male patient with an eyelid mass as the exclusive and initial symptom survived over 13 years. Symptomatic relief was more important than a complete cure for these patients in such a context. However, multiple X-ray exposures may lead to faint erythema and moist desquamation, exacerbated in MF patients. In recent years, percutaneous MWA has been recognized as a safe and effective technique widely used in various fields of medicine. In addition to conventional locations, such as the liver, kidney and thyroid, MWA has been gradually applied to unique sites, such as the bone, lung and bile duct, achieving excellent outcomes[23]. Furthermore, MWA has unique advantages in spherical lesions and superficial locations; thus, this approach was considered suitable for the eyelid mass in this case. Under the guidance of US, operators could observe the ablation range in real-time and with a clear visual of the operation, while needle placement could be flexibly handled to ensure precision. The high temperature causes tissue charring, leading to shrinkage of the mass. Physiologically, malignant CD4+ T cells play a vital role in the development of MF, while Th2 cytokines (which secrete IL-4, IL-5 and IL-10) account for the majority of lymphocytes arising from CD4+ Th0 cells[24]. Dumolard et al[25] reported that IL-12 secretion increases and IL-4 and IL-10 secretion decreases after MWA, thus inducing an antitumour effect. Based on this finding, it was presumed that MWA plus immunotherapy combination therapy might enhance the antitumour immune response and improve the curative effect of MF. Nevertheless, the patient refused other higher-level treatment options for several reasons. Further studies remain to be conducted to investigate whether repeated MWA can improve the efficacy of immunotherapy in MF patients.

Table 1 Clinical characteristics of cases of advanced-stage mycosis fungoides eyelid involvement.
Ref.
Gender
Age
Tumor position
Physical signs
Treatment
Survival
Jusufbegovic et al[17], 2015Male50sLeft lower eyelidPeriorbital edemaRadiotherapy, chemotherapy, and multiple facial reconstructive surgery> 13 yr
Chokoeva et al[18], 2015Male64Right upper eyelidSolitary ulcerated-necrotic lesionCHOP chemotherapy regimenSeveral months
Gül et al[19], 2008Female33Right eyelidInfiltrative plaques and tumoral lesionsRadiotherapy
Kiratli et al[20], 2006Male67Left lower eyelidThickened skin with pigment spotsCVP chemotherapy regimen4 mo
Male56Right eyelidDecreased vision in the right eyePUVA therapy and CVP chemotherapy regimen2 mo
Ing et al[21], 2005Male72Left upper and right lower eyelidsSkin ulcerationsOcular lubrication and radiotherapySeveral months
Game et al[22], 2002Male72Left lower eyelidErythematous lesionElectron beam therapy

The psychological status of haematologic malignancy patients requires more attention due to the poor prognosis and need for repeated treatments. Recent research has also demonstrated that palliative treatments are feasible and acceptable, which promises improvements in patient care[26]. In this case, the patient exhibited serious symptoms of depression and anxiety during chemotherapy. He became irritated and refused to undergo continuous long-term treatment even though he was in a deteriorated condition. After receiving MWA, his mental condition recovered gradually when he realized that the mass had shrunk. Additionally, palliative treatments such as MWA also reflect humanistic care for patients, which plays a crucial role in subsequent treatment episodes.

CONCLUSION

We described a male patient with advanced-stage MF eyelid involvement who underwent US-guided MWA. In this case, MWA was shown to be a safe and effective treatment for preventing the mass from further compressing the eyeball, and it may also play a remarkable role in dramatically alleviating patients’ clinical symptoms and anxiety. Regrettably, the patient did not receive more advanced treatments, and the therapeutic value of WMA in combination with other modalities deserves further investigation.

Footnotes

Provenance and peer review: Unsolicited article; Externally peer reviewed.

Peer-review model: Single blind

Specialty type: Radiology, nuclear medicine and medical imaging

Country/Territory of origin: China

Peer-review report’s scientific quality classification

Grade A (Excellent): 0

Grade B (Very good): B

Grade C (Good): 0

Grade D (Fair): 0

Grade E (Poor): 0

P-Reviewer: Sartori S, Italy S-Editor: Zhang H L-Editor: A P-Editor: Zhang H

References
1.  Mahalingam M, Reddy VB. Mycosis Fungoides, Then and Now… Have We Travelled? Adv Anat Pathol. 2015;22:376-383.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 1]  [Article Influence: 0.1]  [Reference Citation Analysis (0)]
2.  Yeşiltaş YS, Hoşal MB, Yüksel MK, Okçu Heper A. Severe upper eyelid mass in a patient with mycosis fungoides. Orbit. 2020;39:150-152.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
3.  Larocca C, Kupper T. Mycosis Fungoides and Sézary Syndrome: An Update. Hematol Oncol Clin North Am. 2019;33:103-120.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 15]  [Cited by in F6Publishing: 14]  [Article Influence: 7.5]  [Reference Citation Analysis (0)]
4.  Hernández JI, Cepeda MF, Valdés F, Guerrero GD. Microwave ablation: state-of-the-art review. Onco Targets Ther. 2015;8:1627-1632.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 9]  [Cited by in F6Publishing: 12]  [Article Influence: 1.3]  [Reference Citation Analysis (0)]
5.  Vogl TJ, Nour-Eldin NA, Hammerstingl RM, Panahi B, Naguib NNN. Microwave Ablation (MWA): Basics, Technique and Results in Primary and Metastatic Liver Neoplasms - Review Article. Rofo. 2017;189:1055-1066.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 47]  [Cited by in F6Publishing: 39]  [Article Influence: 9.4]  [Reference Citation Analysis (0)]
6.  Willemze R, Jaffe ES, Burg G, Cerroni L, Berti E, Swerdlow SH, Ralfkiaer E, Chimenti S, Diaz-Perez JL, Duncan LM, Grange F, Harris NL, Kempf W, Kerl H, Kurrer M, Knobler R, Pimpinelli N, Sander C, Santucci M, Sterry W, Vermeer MH, Wechsler J, Whittaker S, Meijer CJ. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105:3768-3785.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 2545]  [Cited by in F6Publishing: 2060]  [Article Influence: 149.7]  [Reference Citation Analysis (0)]
7.  Ahn CS, ALSayyah A, Sangüeza OP. Mycosis fungoides: an updated review of clinicopathologic variants. Am J Dermatopathol. 2014;36:933-948.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 35]  [Cited by in F6Publishing: 13]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
8.  Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, Robson A, Calonje E, Stefanato CM, Wain EM, Wilkins B, Fields PA, Dean A, Webb K, Scarisbrick J, Morris S, Whittaker SJ. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28:4730-4739.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 448]  [Cited by in F6Publishing: 119]  [Article Influence: 37.3]  [Reference Citation Analysis (0)]
9.  Kamijo H, Miyagaki T. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy. Curr Treat Options Oncol. 2021;22:10.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Cited by in F6Publishing: 2]  [Article Influence: 1.0]  [Reference Citation Analysis (0)]
10.  Hughes CF, Khot A, McCormack C, Lade S, Westerman DA, Twigger R, Buelens O, Newland K, Tam C, Dickinson M, Ryan G, Ritchie D, Wood C, Prince HM. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125:71-81.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 117]  [Cited by in F6Publishing: 100]  [Article Influence: 16.7]  [Reference Citation Analysis (0)]
11.  Jawed SI, Myskowski PL, Horwitz S, Moskowitz A, Querfeld C. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol. 2014;70:205.e1-16; quiz 221.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 162]  [Cited by in F6Publishing: 149]  [Article Influence: 20.3]  [Reference Citation Analysis (0)]
12.  Erridge S, Pucher PH, Markar SR, Malietzis G, Athanasiou T, Darzi A, Sodergren MH, Jiao LR. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg. 2017;104:1433-1442.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 36]  [Cited by in F6Publishing: 38]  [Article Influence: 7.2]  [Reference Citation Analysis (0)]
13.  Nikfarjam M, Muralidharan V, Christophi C. Mechanisms of focal heat destruction of liver tumors. J Surg Res. 2005;127:208-223.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 211]  [Cited by in F6Publishing: 180]  [Article Influence: 12.4]  [Reference Citation Analysis (0)]
14.  Facciorusso A, Di Maso M, Muscatiello N. Microwave ablation versus radiofrequency ablation for the treatment of hepatocellular carcinoma: A systematic review and meta-analysis. Int J Hyperthermia. 2016;32:339-344.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 116]  [Cited by in F6Publishing: 109]  [Article Influence: 19.3]  [Reference Citation Analysis (0)]
15.  Yi Y, Zhang Y, Wei Q, Zhao L, Han J, Song Y, Ding Y, Lu G, Liu J, Ding H, Dai F, Tang X. Radiofrequency ablation or microwave ablation combined with transcatheter arterial chemoembolization in treatment of hepatocellular carcinoma by comparing with radiofrequency ablation alone. Chin J Cancer Res. 2014;26:112-118.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in F6Publishing: 11]  [Reference Citation Analysis (0)]
16.  Tian Z, Cheng Y, Dong T, Gao X, Nan Q.   Numerical Study for Lung Microwave Ablation in Different Thermal and Electrical Properties. In: Lhotska L, Sukupova L, Lacković I, Ibbott G. World Congress on Medical Physics and Biomedical Engineering 2018. Springer: Singapore, 2018: 563-566.  [PubMed]  [DOI]  [Cited in This Article: ]
17.  Jusufbegovic D, Char DH. Clinical variability of ocular involvement in mycosis fungoides. JAMA Ophthalmol. 2015;133:341-343.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Cited by in F6Publishing: 6]  [Article Influence: 1.1]  [Reference Citation Analysis (0)]
18.  Chokoeva AA, Tchernev G. Mycosis Fungoides: The Multicentric Tumor D'emblee. Mayo Clin Proc. 2015;90:1746-1747.  [PubMed]  [DOI]  [Cited in This Article: ]  [Reference Citation Analysis (0)]
19.  Gül U, Soylu S, Aslan E, Yazar Z, Demiriz M. Uncommon presentation of mycosis fungoides: eyelid margin involvement. J Dermatol. 2008;35:581-584.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 11]  [Cited by in F6Publishing: 7]  [Article Influence: 0.8]  [Reference Citation Analysis (0)]
20.  Kiratli H, Gümüs K. [Mycosis fungoides of the eyelids. Two case reports]. J Fr Ophtalmol. 2006;29:323-326.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 1]  [Article Influence: 0.1]  [Reference Citation Analysis (0)]
21.  Ing E, Hsieh E, Macdonald D. Cutaneous T-cell lymphoma with bilateral full-thickness eyelid ulceration. Can J Ophthalmol. 2005;40:467-468.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 8]  [Article Influence: 0.5]  [Reference Citation Analysis (0)]
22.  Game JA, Davies R. Mycosis fungoides causing severe lower eyelid ulceration. Clin Exp Ophthalmol. 2002;30:369-371.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 13]  [Cited by in F6Publishing: 6]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
23.  Vogl TJ, Nour-Eldin NA, Albrecht MH, Kaltenbach B, Hohenforst-Schmidt W, Lin H, Panahi B, Eichler K, Gruber-Rouh T, Roman A. Thermal Ablation of Lung Tumors: Focus on Microwave Ablation. Rofo. 2017;189:828-843.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 23]  [Cited by in F6Publishing: 20]  [Article Influence: 4.6]  [Reference Citation Analysis (0)]
24.  Kim EJ, Hess S, Richardson SK, Newton S, Showe LC, Benoit BM, Ubriani R, Vittorio CC, Junkins-Hopkins JM, Wysocka M, Rook AH. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115:798-812.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 139]  [Cited by in F6Publishing: 81]  [Article Influence: 8.2]  [Reference Citation Analysis (0)]
25.  Dumolard L, Ghelfi J, Roth G, Decaens T, Macek Jilkova Z. Percutaneous Ablation-Induced Immunomodulation in Hepatocellular Carcinoma. Int J Mol Sci. 2020;21.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 5]  [Cited by in F6Publishing: 4]  [Article Influence: 2.5]  [Reference Citation Analysis (0)]
26.  El-Jawahri A, Nelson AM, Gray TF, Lee SJ, LeBlanc TW. Palliative and End-of-Life Care for Patients With Hematologic Malignancies. J Clin Oncol. 2020;38:944-953.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 24]  [Cited by in F6Publishing: 4]  [Article Influence: 12.0]  [Reference Citation Analysis (0)]